NYSE:MRK

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

By early afternoon Tuesday, Merck & Co. shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and Merck together contributed an estimated ~36 points to the index’s ~386‑point climb at that time. MarketWatch

11 November 2025

NYSE:MRK·Stock Market

Dow Falls as Palantir Plunges – Is the AI Stock Boom Turning into a Bubble?

Stock trading to kick off November has been a tale of two markets. High-tech and growth stocks are extending their momentum, while old-line blue chips struggle. On Monday, the benchmark S&P 500 and Nasdaq Composite managed to close higher – up 0.17% and 0.46%, respectively – even as the Dow Jones Industrial Average fell nearly half a percentreuters.com. This split reflects the radically different fortunes of tech-focused firms versus more traditional industries.

4 November 2025

Artificial Intelligence·NASDAQ:AMD·NASDAQ:AMZN·NASDAQ:MSFT·NASDAQ:NVDA·NASDAQ:ORCL·NASDAQ:PLTR·NYSE:MRK·NYSE:UNH·Stock Market

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecastsmarketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10%marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook while slightly raising profit guidancemarketscreener.com, a cautious stance that likely weighed on the share price.

30 October 2025

Earnings Reports·NYSE:MRK·Pharmaceuticals·Stock Market

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck & Co. is a global healthcare company organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease, cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in H1 2025nasdaq.com. Other pillars include GARDASIL® and type-2 diabetes drugs. Merck invests heavily in R&D, with hundreds of projects in clinical development. In mid-2025 the company announced a transformation plan to reallocate resources toward “new growth drivers” – including acquisitions and upcoming product launches – to drive long-term innovationmerck.com.

11 October 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

For the period August 16–17, 2025, the biotech, pharma, medical, and health sectors saw a range of significant developments worldwide. Below is a comprehensive roundup of top stories categorized by theme, complete with expert insights and source links:

17 August 2025

NASDAQ:BLUE·NASDAQ:CRSP·NASDAQ:GBT·NASDAQ:VRTX·NYSE:MRK·NYSE:PFE·Pharmaceutical News

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

This 48-hour period brought a flurry of major developments in biotechnology, pharmaceuticals, medicine and public health worldwide – from game-changing clinical trial victories and regulatory decisions to urgent health policy actions and scientific breakthroughs. Below is a comprehensive roundup of the top news from August 10–11, 2025.

11 August 2025

LSE:GSK·NYSE:MRK·NYSE:NVS·PSE:AC·Stock Market